What you should know:
1. Bone Biologics concluded a preclinical study of rhNELL-1. Researchers found the product was well tolerated with no inflammation.
2. Bone Biologics intends to build on the preclinical results and launch a clinical trial at a later date.
3. Researchers tested the rhNELL-1 product on sheep, finding increases in fusion and quantity of bone when compared to a control.
4. Bone Biologics received approval to test rhNELL-1 on 30 patients in Australia in a multicenter pilot clinical trial.
More articles on biologics:
Dr. Bryan Little appointed to state medical board, task force
Former Medtronic, Bioventus executive becomes CEO at BlueWind Medical
Exactech co-founders retire, current CEO to transition to board role — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
